Skip to main content

Table 1 Profiles of participants and clinical resoponses

From: Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

Patient no.

Age

Gender

Dose of peptide (mg)

Number of vaccination

Adverse events

DTH skin test

Evaluation of CT images

1

69

M

0.1

1

-

-

PD

2

32

M

0.1

3

-

-

PD

3

21

F

0.1

6

-

-

PD

4

21

M

1.0

6

-

-

PD

5

39

F

1.0

6

Fever

-

NC

6

26

M

1.0

4

-

-

PD

  1. PD: progressive disease, NC: no change